Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/kras-mutation-in-colon-cancer-a-marker-of-resistance-to-egfr-i-therapy-f35n8hHBzS
References (69)
-
S. Tejpar, H. Piessevaux, K. Claes, P. Piront, J. Hoenderop, C. Verslype, E. Cutsem (2007)
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.The Lancet. Oncology, 8 5
-
E. Figueiredo, R. Mehta, Xinjian Peng, R. Mehta, G. Murillo (2009)
Abstract #7: Characterization of a normal human colonic epithelial cell line as a model to study vitamin D action in colon cancer prevention.Cancer Research, 69
-
M. Veronese, W. Sun, B. Giantonio, J. Berlin, J. Shults, L. Davis, D. Haller, P. O'dwyer (2005)
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancerBritish Journal of Cancer, 92
-
M. Esteller, S. González, R. Risques, E. Marcuello, R. Mangues, J. Germà, J. Herman, G. Capellá, M. Peinado (2001)
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
-
C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille, T. Price, L. Shepherd, H. Au, C. Langer, M. Moore, J. Zalcberg (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.The New England journal of medicine, 359 17
-
U. Dailey
Cancer,Facts and Figures about.Journal of the National Medical Association, 14 1
-
J. Rak, Y. Mitsuhashi, L. Bayko, J. Filmus, S. Shirasawa, T. Sasazuki, R. Kerbel (1995)
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.Cancer research, 55 20
-
J. Lee, S. Wang, M. Lai, Y. Lin, H. Yang (1996)
K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.Anticancer research, 16 6B
-
(Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised February 2009.)
Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised February 2009.Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised February 2009., Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised February 2009.
-
W. Samowitz, J. Holden, K. Curtin, S. Edwards, Adrianne Walker, Heather Lin, M. Robertson, Melanie Nichols, Kristen Gruenthal, B. Lynch, M. Leppert, M. Slattery (2001)
Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer.The American journal of pathology, 158 4
-
E. Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky, J. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier (2009)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.The New England journal of medicine, 360 14
-
S. Khambata-Ford, C. Garrett, N. Meropol, M. Basik, C. Harbison, Shujian Wu, T. Wong, Xin Huang, C. Takimoto, A. Godwin, B. Tan, S. Krishnamurthi, H. Burris, E. Poplin, M. Hidalgo, J. Baselga, E. Clark, D. Mauro (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
-
A. Cohn, D. Smith, M. Neubauer, G. Houston, P. Khandelwal, R. Wiggans, K. Zhang, M. Yassine (2016)
Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
G. Finocchiaro, F. Cappuzzo, P. Jänne, K. Bencardino, C. Carnaghi, W. Franklin, M. Roncalli, L. Crinò, A. Santoro, M. Varella-Garcia (2007)
EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancerJournal of Clinical Oncology, 25
-
ImClone Systems Inc; revised -
H. Prenen, J. Schutter, B. Jacobs, W. Roock, B. Biesmans, B. Claes, D. Lambrechts, E. Cutsem, S. Tejpar (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal CancerClinical Cancer Research, 15
-
(2009)
et al. High epiregulin (EREG) plus K-ras (WT) status as predictors of cetuximab benefit in the treatments of advanced colorectal cancer (ACRC): results from NCIC CTG CO.17—a phase III trial of cetuximab versus best supportive care (BSC)J Clin Oncol, 27
-
J. Tol, Miriam Koopman, A. Cats, Cees Rodenburg, G. Creemers, J. Schrama, Frans Erdkamp, A. Vos, C. Groeningen, Harm Sinnige, D. Richel, Emile Voest, Jeroen Dijkstra, M. Vink-Börger, N. Antonini, L. Mol, J. Krieken, O. Dalesio, C.J.A. Punt (2009)
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.The New England journal of medicine, 360 6
-
W. Roock, H. Piessevaux, J. Schutter, M. Janssens, G. Hertogh, N. Personeni, B. Biesmans, J. Laethem, M. Peeters, Y. Humblet, E. Cutsem, S. Tejpar (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Annals of oncology : official journal of the European Society for Medical Oncology, 19 3
-
(2007)
Hyperactive Ras in developmental disorders and cancerNat Rev Cancer, 7
-
S. Siena, J. Tabernero, R. Burkes, J. Cassidy, D. Cunningham, M. Barugel, Y. Humblet, C. McPhie, M. Shing, J. Douillard (2008)
Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety dataJournal of Clinical Oncology, 26
-
J. Westra, M. Schaapveld, H. Hollema, J. Boer, Marian Kraak, D. Jong, A. Elst, N. Mulder, C. Buys, R. Hofstra, J. Plukker (2005)
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
-
E. Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J. Canon, J. Laethem, J. Maurel, G. Richardson, M. Wolf, R. Amado (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
-
Li Ying (2009)
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
C. Allegra, C. Allegra, J. Jessup, M. Somerfield, S. Hamilton, E. Hammond, D. Hayes, Pamela McAllister, R. Morton, R. Schilsky (2009)
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 12
-
(A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination or bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. http://www.clinicaltrials.gov/ct2/show/NCT00265850. Accessed April 18, 2009.)
A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination or bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. http://www.clinicaltrials.gov/ct2/show/NCT00265850. Accessed April 18, 2009.A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination or bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. http://www.clinicaltrials.gov/ct2/show/NCT00265850. Accessed April 18, 2009., A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination or bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. http://www.clinicaltrials.gov/ct2/show/NCT00265850. Accessed April 18, 2009.
-
Daniel Freeman, T. Juan, M. Reiner, J. Hecht, N. Meropol, J. Berlin, E. Mitchell, I. Sarosi, R. Radinsky, R. Amado (2008)
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.Clinical colorectal cancer, 7 3
-
(SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC. http://www.clinicaltrials.gov/ct2/show/NCT00418938. Accessed April 18, 2009.)
SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC. http://www.clinicaltrials.gov/ct2/show/NCT00418938. Accessed April 18, 2009.SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC. http://www.clinicaltrials.gov/ct2/show/NCT00418938. Accessed April 18, 2009., SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC. http://www.clinicaltrials.gov/ct2/show/NCT00418938. Accessed April 18, 2009.
-
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, E. Cutsem (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.The New England journal of medicine, 351 4
-
D. Jonker, C. Karapetis, C. Harbison, C. O'Callaghan, D. Tu, R. Simes, L. Xu, M. Moore, J. Zalcberg, S. Khambata-Ford (2016)
High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
M. Étienne-Grimaldi, J. Formento, M. Francoual, E. François, P. Formento, N. Renée, P. Laurent-Puig, M. Chazal, D. Benchimol, J. Delpero, C. Létoublon, D. Pezet, J. Seitz, G. Milano (2008)
K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine TherapyClinical Cancer Research, 14
-
E. Fearon, B. Vogelstein (1990)
A genetic model for colorectal tumorigenesisCell, 61
-
Marcos Malumbres, M. Barbacid (2003)
RAS oncogenes: the first 30 yearsNature Reviews Cancer, 3
-
S. Benvenuti, A. Sartore-Bianchi, F. Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena, A. Bardelli (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.Cancer research, 67 6
-
(2009)
Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; revised -
(2009)
Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) -
Edith Mitchell, M. Lacouture, H. Shearer, N. Iannotti, Bilal Piperdi, M. Pillai, Feng Xu, M. Yassine (2009)
Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
H. Hurwitz, J. Yi, William Ince, W. Novotny, O. Rosen (2009)
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.The oncologist, 14 1
-
H. Bouzourène, P. Gervaz, J. Cerottini, J. Benhattar, P. Chaubert, E. Saraga, S. Pampallona, F. Bosman, J. Givel (2000)
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.European journal of cancer, 36 8
-
Chronic Division (2010)
Cancer facts and figures -
A. Russo, V. Bazan, V. Agnese, V. Rodolico, N. Gebbia (2005)
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.Annals of oncology : official journal of the European Society for Medical Oncology, 16 Suppl 4
-
M. Domingues, Y. Menezes, F. Ostronoff, R. Calixto, R. Florêncio, A. Sucupira, Ana Souto-Maior, M. Ostronoff (2009)
Coexistence of Leishmaniasis and Hodgkin's lymphoma in a lymph node.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 32
-
(Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests (abstract 1811). Paper presented at: 99th AACR Annual Meeting; 2008; San Diego, CA.)
Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests (abstract 1811). Paper presented at: 99th AACR Annual Meeting; 2008; San Diego, CA.Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests (abstract 1811). Paper presented at: 99th AACR Annual Meeting; 2008; San Diego, CA., Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests (abstract 1811). Paper presented at: 99th AACR Annual Meeting; 2008; San Diego, CA.
-
Dennis Ahnen, Polly Feigl, Gang Quan, Cecelia Fenoglio-preiser, Laura Lovato, P. Bunn, Grant Stemmerman, John Wells, John Macdonald, F. Meyskens (1998)
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.Cancer research, 58 6
-
F. Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli (2008)
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 35
-
K. Furuse (1995)
[Phase III study].Gan to kagaku ryoho. Cancer & chemotherapy, 22 5
-
R. Amado, M. Wolf, M. Peeters, E. Cutsem, S. Siena, Daniel Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. Patterson, David Chang (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
-
S. Cohn, A. Pearson, W. London, T. Monclair, P. Ambros, G. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, V. Mosseri, T. Simon, A. Garaventa, V. Castel, K. Matthay (2009)
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 2
-
E. Mitchell, R. Perez-soler, E. Cutsem, M. Lacouture (2007)
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.Oncology, 21 11 Suppl 5
-
R. Goldberg, A. Venook, R. Schilsky (2004)
Cetuximab in the treatment of colorectal cancer.Clinical advances in hematology & oncology : H&O, 2 11
-
A. Lièvre, J. Bachet, V. Boige, A. Cayre, D. Corre, E. Buc, M. Ychou, O. Bouché, B. Landi, C. Louvet, T. André, F. Bibeau, M. Diebold, P. Rougier, M. Ducreux, G. Tomasic, J. Emile, F. Penault-Llorca, P. Laurent-Puig (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 3
-
J. Benhattar, L. Losi, P. Chaubert, J. Givel, José Costa (1993)
Prognostic significance of K-ras mutations in colorectal carcinoma.Gastroenterology, 104 4
-
A. Lièvre, J. Bachet, D. Corre, V. Boige, B. Landi, J. Emile, J. Côté, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Cancer research, 66 8
-
(Erbitux (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Inc; revised November 2008.)
Erbitux (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Inc; revised November 2008.Erbitux (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Inc; revised November 2008., Erbitux (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Inc; revised November 2008.
-
Suzanne Schubbert, K. Shannon, G. Bollag (2007)
Hyperactive Ras in developmental disorders and cancerNature Reviews Cancer, 7
-
C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio, F. Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, A. Loos, A. Zubel, P. Koralewski (2009)
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
M. Federico, S. Luminari, E. Iannitto, G. Polimeno, L. Marcheselli, Antonella Montanini, A. Sala, F. Merli, C. Stelitano, S. Pozzi, R. Scalone, N. Renzo, P. Musto, L. Baldini, G. Cervetti, F. Angrilli, P. Mazza, M. Brugiatelli, P. Gobbi (2009)
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
-
Erbitux (cetuximab) [prescribing information -
F. Loupakis, A. Ruzzo, C. Cremolini, B. Vincenzi, L. Salvatore, D. Santini, G. Masi, I. Stasi, E. Canestrari, E. Rulli, I. Floriani, K. Bencardino, N. Galluccio, V. Catalano, G. Tonini, Mauro Magnani, G. Fontanini, F. Basolo, A. Falcone, F. Graziano (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBritish Journal of Cancer, 101
-
(2008)
A comparability study of 4 commercial KRAS tests (abstract 1811) -
(2009)
SPIRITT-Q2W FOLFIRI regimen plus panitumumab or a Q2W FOLFIRI regimen plus bevacizumab for 2nd-line mCRC -
A. Sartore-Bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Nicolantonio, P. Saletti, S. Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli (2009)
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.Cancer research, 69 5
-
J. Krieken, A. Jung, T. Kirchner, F. Carneiro, R. Seruca, F. Bosman, P. Quirke, J. Fléjou, T. Hansen, G. Hertogh, P. Jares, C. Langner, G. Hoefler, M. Ligtenberg, D. Tiniakos, S. Tejpar, G. Bevilacqua, A. Ensari (2008)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Archiv, 453
-
M. Peeters, G. Wilson, M. Ducreux, A. Cervantes, T. André, Y. Hotko, F. Lordick, S. Collins, M. Shing, T. Price (2008)
Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety resultsJournal of Clinical Oncology, 26
-
(2007)
Cetuximab for the treatment of colorectal cancerN Engl J Med, 357
-
C. Townsley, P. Major, L. Siu, J. Dancey, E. Chen, G. Pond, T. Nicklee, J. Ho, D. Hedley, M. Tsao, M. Moore, A. Oza (2006)
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancerBritish Journal of Cancer, 94
-
B. Vogelstein, E. Fearon, S. Hamilton, S. Kern, Antonette Preisinger, M. Leppert, Y. Nakamura, R. White, A. Smits, J. Bos (1988)
Genetic alterations during colorectal-tumor development.The New England journal of medicine, 319 9
-
(American Cancer Society. Cancer facts and figures. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 25, 2009.)
American Cancer Society. Cancer facts and figures. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 25, 2009.American Cancer Society. Cancer facts and figures. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 25, 2009., American Cancer Society. Cancer facts and figures. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 25, 2009.
-
(Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Paper presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA.)
Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Paper presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA.Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Paper presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA., Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Paper presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA.
- Publisher
- Springer Journals
- Copyright
- Copyright © 2009 by The Author(s)
- Subject
- Medicine & Public Health; Surgery ; Oncology ; Surgical Oncology
- ISSN
- 1068-9265
- eISSN
- 1534-4681
- DOI
- 10.1245/s10434-009-0811-z
- pmid
- 19936839
- Publisher site
- See Article on Publisher Site
Abstract
Future studies investigating EGFR-I therapy in mCRC should incorporate KRAS mutation testing into the study protocol in order to more accurately determine the patient population that will obtain clinical benefit from these novel agents.
Journal
Annals of Surgical Oncology – Springer Journals
Published: Nov 20, 2009